Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Faslodex Fulvestrant Locally advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete
Fentora Fentanyl buccal Pain (breakthrough), cancer (adults) Do not reimburse Complete
Ferinject ferric carboxymaltose Iron deficiency anemia Active
Ferinject ferric carboxymaltose Iron deficiency in adult patients with heart failure Active
Ferriprox deferiprone Transfusional iron overload Reimburse with clinical criteria and/or conditions Complete
Ferriprox Deferiprone Transfusional iron overload List with clinical criteria and/or conditions Complete
Fibristal ulipristal acetate Uterine fibroids (signs and symptoms) Reimburse with clinical criteria and/or conditions Complete
Fibristal ulipristal acetate Uterine fibroids (signs and symptoms) Reimburse with clinical criteria and/or conditions Complete
Fibristal Ulipristal acetate Uterine fibroids List with criteria/condition Complete
Finacea Azelaic acid Rosacea List Complete